Cash Flow Statement

Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Cash from Restructuring Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Inventory Change in Inventory Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Preferred Shares Issued Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Others

Ratios

LENZ Therapeutics (LENZ) Asset Writedowns and Impairment (2025)

LENZ Therapeutics (LENZ) has disclosed Asset Writedowns and Impairment for 1 consecutive years, with $82000.0 as the latest value for Q1 2025.

Quarterly Asset Writedowns and Impairment changed N/A to $82000.0 in Q1 2025 from the year-ago period, while the trailing twelve-month figure was $82000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $82000.0 for FY2025, N/A changed from the prior year.
Asset Writedowns and Impairment for Q1 2025 was $82000.0 at LENZ Therapeutics.
The five-year high for Asset Writedowns and Impairment was $82000.0 in Q1 2025, with the low at $82000.0 in Q1 2025.